Community-based study of fatty liver in older adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort will enroll elderly residents with ultrasound- or FibroScan-diagnosed fatty liver from a community setting. Researchers will track metabolic, cardiovascular, liver fibrosis, and sarcopenia risk factors over time to understand progression patterns. The goal is to build a health risk assessment framework tailored to elderly Chinese patients with fatty liver and identify potential points for targeted intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ① Elderly people aged ≥65 years among permanent residents (living for more than 5 years) in the survey area;

  * Imaging diagnosis (ultrasound or FibroScan/FibroTouch) of fatty liver; -③ Voluntary participation in this study and signing an informed consent form.

Exclusion Criteria:

* ①Major disability, mental illness, major wasting disease, severe cardiac, pulmonary and renal insufficiency;

  * Patients with combined primary liver cancer or other types of cancer; -③Patients who have received liver transplant or other organ transplants.

Where it's running

• NO.518 Shangtang Road
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Wei Zhang, DR
• Email: zhangwei969696@163.com
• Phone: +8613567135527

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low‑methoxy pectin for inflammation, gut microbiome, and metabolic health in MASLD

  This tests whether taking daily low‑methoxy pectin for six weeks can reduce inflammation and improve gut bacteria and metabolic markers in adults with MASLD.

  Recruiting at 3 sites University of Nottingham · Nottingham, United Kingdom and 2 other locations · NCT07093346

• HP515 for non-alcoholic fatty liver disease (NASH/MASH)

  This trial tests whether daily HP515 tablets can reduce liver fat and are safe in adults (18–65) with non-alcoholic fatty liver disease and liver fat ≥10%.

  Recruiting Phase 2 Hinova Pharmaceuticals Inc. · Beijing, Beijing Municipality and 1 other locations · NCT07308548

• Ultrasound method to measure liver fat percentage

  This study will test whether a new ultrasound technique can accurately measure the percentage of fat in the liver for adults with or at risk for MASLD (formerly NAFLD) and for healthy volunteers.

  Recruiting ContextVision AB · Seattle, Washington · NCT07270601

• Multiple under-the-skin injections of B1344 for adults with NAFLD and NASH

  This trial will test whether repeated subcutaneous injections of an experimental drug called B1344 are safe and affect liver fat and related measures in adults with NAFLD or NASH.

  Recruiting Phase 1 Tasly Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 4 other locations · NCT07128797

• Telehealth program for weight management and related health issues

  This study is testing a new telehealth program for weight management to see if it helps obese adults with type 2 diabetes and liver issues lose weight and improve their health better than traditional in-person programs.

  Recruiting Changi General Hospital · Singapore · NCT06890169

• ECC4703 with Sulfasalazine and Pitavastatin in adults with NAFLD and dyslipidemia

  This early study tests whether adding ECC4703 to sulfasalazine and pitavastatin is safe and how the body handles the combination in adults with fatty liver disease and high cholesterol.

  Recruiting Phase 1 Eccogene · Melbourne, Victoria · NCT07726368

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.